Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: Camptothecin-based prodrug nanomedicines for cancer therapy
Renshuai
Zhang
a,
Jing
Yu
b,
Zhu
Guo
*ac,
Hongfei
Jiang
*a and
Chao
Wang
*a
aCancer Institute of The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266061, China. E-mail: guozhugz@126.com; jianghongfei@qdu.edu.cn; wangchao@qdu.edu.cn
bQingdao Hospital, University of Health and Rehabilitation Sciences, Qingdao Municipal Hospital, Qingdao, 266071, China
cThe Affiliated Hospital of Qingdao University, Qingdao 266061, China
First published on 9th January 2025
Abstract
Correction for ‘Camptothecin-based prodrug nanomedicines for cancer therapy’ by Renshuai Zhang et al., Nanoscale, 2023, 15, 17658–17697, https://doi.org/10.1039/D3NR04147F.
The authors regret that project funders were omitted from the Acknowledgements section in the published article. The corrected Acknowledgements section should read as follows.
This study was supported by the National Natural Science Foundation of China (82202848), the Shandong Postdoctoral Science Foundation (SDCX-ZG-202203015), and the Natural Science Foundation of Shandong Province (grant no. ZR2021MC189).
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2025 |